Full Paper
pentane; yield=0.22 g as a colourless liquid (0.99 mmol, 62%);
1H NMR (400 MHz, CDCl3): d=3.45 (d, 2H, BrCH2, J=4.8 Hz), 1.60
(m, 1H, BrCH2CH), 1.44–1.17 (m, 12H, CH2), 0.91 ppm (t, 6H, CH3,
J=7.2 Hz).
CD3CN/CDCl3, 1:1 (v/v)): d=8.93 (d, 2H, BipyH, J=6.8 Hz), 8.91 (d,
2H, BipyH, J=6.8 Hz), 8.40 (m, 4H, BipyH), 7.02 (s, 1H, ArH), 6.73
(d, 2H, ortho-ArH, J=0.8 Hz), 4.67 (t, 2H, NCH2, J=7.6 Hz), 4.62 (t,
2H, NCH2, J=7.2 Hz), 4.00 (t, 2H, OCH2, J=6.4 Hz), 2.14 (dd, 2H,
CH2, J=8 Hz), 2.04 (dd, 2H, CH2, J=7 Hz), 1.86 (dd, 2H, Ar-OCH2-
CH2, J=7.6 Hz), 1.61 (dd, 2H, CH2, J=7.2 Hz), 1.40 (m, 4H, CH2)
1.30 (s, 18H, CH3), 0.93 ppm (t, 3H, CH3, J=6.8 Hz); 13C NMR
(75 MHz, CD3CN/CDCl3, 1:1 (v/v)): d=158.17, 151.71, 149.44, 149.38,
145.10, 126.82, 114.34, 108.35, 66.60, 61.84, 61.73, 34.33, 30.62,
30.43, 30.34, 28.11, 27.29, 22.10, 21.38, 12.94 ppm; MALDI-TOF MS
(m/z): 502.43 [Mꢁ2PF6]+.
8-(Bromomethyl)pentadecane (14): The triphenylphosphine dibro-
mide suspension was prepared from triphenylphosphine (1.4 g,
5.4 mmol) and bromine (0.28 mL, 5.5 mmol) in dichloromethane
(20 mL). Alcohol solution: 2-heptylnonan-1-ol (1.0 g, 4.1 mmol) and
pyridine (0.90 mL, 11 mmol) in dichloromethane (4 mL); eluent: n-
heptane; yield=1.0 g as a white solid (3.3 mmol, 80%); 1H NMR
(400 MHz, CDCl3): d=3.45 (d, 2H, BrCH2, J=4.8 Hz), 1.59 (m, 1H,
BrCH2CH), 1.43–1.19 (m, 24H, CH2), 0.89 ppm (t, 6H, CH3, J=
7.2 Hz).
1-[5-(3,5-Di-tert-butylphenoxy)pentyl]-1’-isobutyl-4,4’-bipyridine-
1,1’-diium dihexafluorophosphate (V2): Bromide solution:
(91 mg, 0.18 mmol) and 4 (26 mg, 0.19 mmol) in DMF (1 mL).
Yield=20 mg as
white solid (0.026 mmol, 14%); 1H NMR
2
18-(Bromomethyl)pentatriacontane (15): The triphenylphosphine
dibromide suspension was prepared from triphenylphosphine
(0.66 g, 2.5 mmol) and bromine (0.13 mL, 2.5 mmol) in dichlorome-
thane (10 mL). Alcohol solution: 2-Heptadecylnonadecan-1-ol
(1.0 g, 1.9 mmol) and pyridine (0.40 mL, 5.0 mmol) in dichlorome-
thane (2 mL); eluent: n-heptane; yield=0.90 g as a white solid
a
(400 MHz, CD3CN/CDCl3, 1:1 (v/v)): d=8.93 (d, 2H, BipyH, J=
6.4 Hz), 8.87 (d, 2H, BipyH, J=6.4 Hz), 8.40 (m, 4H, BipyH), 7.02 (s,
1H, para-ArH), 6.73 (d, 2H, ortho-ArH, J=1.2 Hz), 4.67 (t, 2H, NCH2,
J=7.2 Hz), 4.47 (d, 2H, NCH2, J=7.2 Hz), 4.00 (t, 2H, OCH2, J=
6.4 Hz), 2.32 (m, 1H, CH), 2.15 (m, under water peak, 2H, CH2), 1.86
(dd, 2H, CH2, J=7.6 Hz), 1.61 (dd, 2H, CH2, J=7.2 Hz), 1.30 (s, 18H,
CH3), 1.02 ppm (d, 6H, CH3, J=6.4 Hz); 13C NMR (75 MHz, CD3CN/
CDCl3, 1:1 (v/v)): d=158.18, 151.74, 145.19, 145.13, 126.82, 126.79,
114.37, 108.32, 67.94, 66.59, 61.68, 34.29, 30.51, 28.08, 22.09,
18.04 ppm; MALDI-TOF MS (m/z): 488.18 (Mꢁ2PF6)+; HRMS (ESI):
m/z: calcd for C33H48F6N2O1P1: 633.3408 [MꢁPF6]+; found: 633.3396.
1
(1.5 mmol, 79%); H NMR (400 MHz, CDCl3): d=3.45 (d, 2H, BrCH2,
J=4.8 Hz), 1.58 (m, 1H, BrCH2CH), 1.43–1.19 (m, 24H, CH2),
0.88 ppm (t, 6H, CH3, J=7.2 Hz).
1-Adamantyl-4-(pyridin-4-yl)pyridinium
hexafluorophosphate
(17): This compound was synthesized according to a literature pro-
cedure.[20] 1H NMR (400 MHz, CD3CN/CDCl3, 1:1 v/v): d=9.04 (d, 2H,
BipyH, J=6.8 Hz), 8.85 (d, 2H, BipyH, J=6.4 Hz), 8.33 (d, 2H, BipyH,
J=6.4 Hz), 7.82 (d, 2H, BipyH, J=6.4 Hz), 2.39 (m, 3H, adamanta-
neCH), 2.32 (m, 6H, amantane CH2), 1.84 ppm (m, 6H, adamantane
CH2).
1-(Cyclohexylmethyl)-1’-[5-(3,5-di-tert-butylphenoxy)pentyl]-4,4’-
bipyridine-1,1’-diium dihexafluorophosphate (V3): Bromide solu-
tion: 2 (91 mg, 0.18 mmol) and 5 (33 mg, 0.19 mmol) in DMF
1
(1 mL). Yield=50 mg as a white solid (0.061 mmol, 34%); H NMR
1-(Pentatriacontan-18-yl)-4-(pyridin-4-yl)pyridinium
bromide
(400 MHz, CD3CN/CDCl3, 1:1 (v/v)): d=8.94 (d, 2H, BipyH, J=
7.2 Hz), 8.85 (d, 2H, BipyH, J=7.2 Hz), 8.42 (d, 2H, BipyH, J=
3.6 Hz), 8.41 (d, 2H, BipyH, J=3.2 Hz), 7.02 (t, 1H, para-ArH, J=
1.6 Hz), 6.73 (d, 2H, ortho-ArH, J=1.6 Hz), 4.67 (t, 2H, NCH2, J=
7.6 Hz), 4.48 (d, 2H, NCH2, J=7.6 Hz), 4.00 (t, 2H, OCH2, J=6.4 Hz),
2.12 (dd, 2H, CH2, J=7.6 Hz), 2.00 (m, 1H, CH), 1.86 (dd, 2H, CH2,
J=7.6 Hz), 1.78 (m, 2H), 1.71 (m, 1H), 1.64 (m, 2H), 1.61 (m, 2H,
CH2), 1.30 (s, 18H, CH3), 1.26 (m, 3H), 1.13 ppm (m, 2H); 13C NMR
(75 MHz, CD3CN/CDCl3, 1:1 (v/v)): d=158.15, 151.72, 149.42, 145.13,
126.83, 126.72, 114.35, 108.32, 67.11, 66.57, 61.72, 39.04, 34.33,
30.61, 30.45, 28.94, 28.11, 25.19, 24.72, 22.12 ppm; MALDI-TOF MS
(m/z): 528.21 [Mꢁ2PF6]+; HRMS (ESI): m/z: calcd for C36H52F6N2O1P1:
673.3721 [MꢁPF6]+; found: 673.3715.
(16): Bromide 15 (450 mg, 0.77 mmol) and 4,4’-bipyridine (1.4 g,
9.4 mmol) were dissolved in dry MeCN (20 mL) and the mixture
was gently refluxed for 7 days under an argon atmosphere. After
cooling to room temperature, the mixture was precipitated from
diethyl ether (2ꢁ), toluene (2ꢁ) and then dried in vacuo to obtain
16 as a white solid in a yield of 300 mg (0.41 mmol, 53%). In addi-
tion to 16, also iso-C33 and iso-C31 derivatives, which must be the
result of impurities in the commercially available ketone, were
1
found to be present in the product. H NMR (400 MHz, CDCl3): d=
9.39 (d, 2H, BipyH, J=6.8 Hz), 8.88 (d, 2H, BipyH, J=6.0 Hz), 8.36
(d, 2H, BipyH, J=7.2 Hz), 7.71 (d, 2H, BipyH, J=6.0 Hz), 4.87 (d,
2H, NCH2, J=7.6 Hz), 2.06 (m, 1H, CH), 1.44–1.16 (m, 64H, CH2),
0.88 ppm (t, 6H, CH3, J=6.8 Hz); 13C NMR (75 MHz, CDCl3): d=
153.24, 151.02, 145.47, 140.27, 125.08, 120.95, 65.23, 40.01, 31.44,
29.97, 29.22, 25.58, 22.20, 13.63 ppm; MALDI-TOF MS (m/z): 661.50
[MꢁBr]+, 633.46 [MꢁBr iso-C33]+, 605.43 [MꢁBr iso-C31]+.
1-(2-Butylhexyl)-1’-[5-(3,5-di-tert-butylphenoxy)pentyl]-4,4’-bi-
pyridine-1,1’-diium dihexafluorophosphate (V5): Bromide solu-
tion: 2 (91 mg, 0.18 mmol) and 13 (220 mg, 1.0 mmol) in DMF
1
(1 mL). Yield=17 mg as a white solid (0.020 mmol, 11%); H NMR
(400 MHz, CD3CN/CDCl3, 1:1 (v/v)): d=8.95 (d, 2H, BipyH, J=6 Hz),
8.88 (d, 2H, BipyH, J=6.4 Hz), 8.45 (m, 4H, BipyH), 7.01 (s, 1H,
para-ArH), 6.73 (d, 2H, ortho-ArH, J=1.2 Hz), 4.68 (t, 2H, NCH2, J=
7.6 Hz), 4.53 (d, 2H, NCH2, J=7.2 Hz), 4.00 (t, 2H, OCH2, J=6.4 Hz),
2.15 (m, under water peak, 2H, CH2), 2.08 (m, 1H, CH), 1.86 (dd,
2H, CH2, J=7.6 Hz), 1.62 (dd, 2H, CH2, J=7.2 Hz), 1.40–1.20 (m,
12H, CH2), 1.30 (s, 18H, CH3), 0.90 ppm (t, 6H, CH3, J=6.8 Hz);
13C NMR (75 MHz, CD3CN/CDCl3, 1:1 (v/v)): d=158.15, 151.70,
149.51, 149.35, 145.33, 145.11, 126.86, 126.76, 114.34, 108.34, 66.59,
65.45, 61.77, 39.51, 34.35, 30.67, 30.45, 29.33, 28.13, 27.38, 22.16,
13.18 ppm; MALDI-TOF MS (m/z): 572.10 [Mꢁ2PF6]+; HRMS (ESI):
m/z: calcd for C39H60F6N2O1P1: 717.4347 [MꢁPF6]+; found: 717.4344.
General synthesis of viologen derivatives V1, V2, V3, V5 and
V6
A 25 mL flask, closed with a septum, containing a solution of 2
and primary bromide (3, 4, 5, 6, 13 or 14) in DMF was stirred for
3 days at 958C. After cooling, Et2O was added and the precipitate
was filtered off and washed with 20 mL of Et2O. The resulting solid
was mixed with acetone (2 mL) followed by the addition of an
excess of NH4PF6 (s) and the product was precipitated by the addi-
tion of water (10 mL). The precipitate was filtered off, washed with
water (40 mL) followed by Et2O (10 mL) and then dried to obtain
the corresponding viologen.
1-[5-(3,5-Di-tert-butylphenoxy)pentyl]-1’-pentyl-4,4’-bipyridine-
1,1’-diium dihexafluorophosphate (V1):[7a] Bromide solution: 3
(182 mg, 0.36 mmol) and 2 (540 mg, 3.6 mmol) in DMF (2 mL);
yield=1.9 g as a white solid (2.4 mmol, 67%); 1H NMR (400 MHz,
1-[5-(3,5-Di-tert-butylphenoxy)pentyl]-1’-(2-heptylnonyl)-4,4’-bi-
pyridine-1,1’-diium dihexafluorophosphate (V6): Bromide solu-
tion: 2 (91 mg, 0.18 mmol) and 14 (520 mg, 1.7 mmol) in 1 mL
DMF. Yield=33 mg as a white solid (0.035 mmol, 19%); 1H NMR
Chem. Eur. J. 2014, 20, 1 – 12
9
ꢀ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
&
&
These are not the final page numbers! ÞÞ